Leary, A., Willmott, L., Monk, B. J., Frenel, J.-S., Starks, D. C., Okera, M., … Simpkins, F. (2025). Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066). In Molecular Cancer Therapeutics (Vol. 24, pp. B013–B013). American Association for Cancer Research (AACR). https://doi.org/10.1158/1535-7163.targ-25-b013

Leary, Alexandra, Lyndsay Willmott, Bradley J. Monk, Jean-Sébastien Frenel, David C. Starks, Meena Okera, Angeles Alvarez Secord, et al. “Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066).” In Molecular Cancer Therapeutics, 24:B013–B013. American Association for Cancer Research (AACR), 2025. https://doi.org/10.1158/1535-7163.targ-25-b013.

Leary A, Willmott L, Monk BJ, Frenel J-S, Starks DC, Okera M, et al. Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066). In: Molecular Cancer Therapeutics. American Association for Cancer Research (AACR); 2025. p. B013–B013.

Leary, Alexandra, et al. “Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066).” Molecular Cancer Therapeutics, vol. 24, no. 10_Supplement, American Association for Cancer Research (AACR), 2025, pp. B013–B013. Crossref, doi:10.1158/1535-7163.targ-25-b013.

Leary A, Willmott L, Monk BJ, Frenel J-S, Starks DC, Okera M, Secord AA, O’Malley DM, Martin L, Ouali K, Oehler MK, Goh JC, Slomovitz BM, Lim PC, Shannon CM, Neff R, Backes FJ, Rajendran D, Chung H, Kim D, Li H, Jandial D, Simpkins F. Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066). Molecular Cancer Therapeutics. American Association for Cancer Research (AACR); 2025. p. B013–B013.